Silence Therapeutics Plc American Depository Share - SLN STOCK NEWS

Silence Therapeutics plc (NASDAQ: SLN) will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on May 2 at 3:30 p.m. ET. This event highlights Silence's commitment to innovative biotechnology aimed at silencing diseases through precision-engineered medicines. The presentation will be available via a live webcast on the Company’s website, with an archived replay accessible afterward. Silence Therapeutics specializes in RNA interference to develop medicines targeting genetic expressions involved in disease pathologies. Notable product candidates include SLN360 for reducing cardiovascular risk and SLN124 for hematological disorders. The Company collaborates with leading pharmaceutical companies like AstraZeneca and Mallinckrodt Pharmaceuticals.

Silence Therapeutics, a biotechnology company, announced the publication of preclinical data in the journal Blood linking iron regulation to polycythemia vera (PV) and supporting the therapeutic potential of SLN124. The authors, including researchers from WEHI, found variants of the iron-regulating gene HFE in a study of 440 PV cases versus over 400,000 controls. The findings suggest SLN124, an siRNA targeting TMPRSS6, may help control red blood cell production in PV by increasing hepcidin levels. Currently undergoing SANRECO phase 1/2 trials, SLN124 has rare pediatric disease, orphan drug, and FDA Fast Track designations for PV.

Silence Therapeutics plc (NASDAQ: SLN) announces management's participation in a virtual fireside chat at Guggenheim’s Genomic Medicines and Rare Disease Days on April 4th, 2023, at 2:10 p.m. ET. A live webcast will be accessible through the Investors section of Silence's website, with an archived replay available post-conference. Silence Therapeutics focuses on developing innovative medicines using RNA interference (RNAi) to target disease-related genes. Notable products include SLN360 for cardiovascular risk and SLN124 for hematological diseases. Collaborations with AstraZeneca and others enhance Silence’s research capabilities.

Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) has announced the appointment of Barbara A. Ruskin, Ph.D, J.D., to its Board of Directors, expanding the board to nine members. Dr. Ruskin, who has over 25 years of experience in life sciences and intellectual property law, previously served as Chief Intellectual Property and Innovation Officer at Silence Therapeutics (OTC: SLNCF). Her background includes advising pharmaceutical companies and managing patent portfolios for major biotech firms. The company is focused on developing non-addictive pain management products and is seeking FDA approval for its candidates.

Silence Therapeutics announces the appointment of Dr. Steven Romano as the new Chief Medical Officer and Head of Research and Development, succeeding Dr. Giles Campion, set to retire by year-end 2023. Dr. Romano, a non-executive director since July 2019, boasts over 25 years of pharmaceutical experience, including leadership roles at Mallinckrodt and Pfizer. The transition aims for a seamless leadership change while continuing Silence's growth in RNA interference therapies. Silence has also recently reacquired two siRNA assets from Mallinckrodt, indicative of ongoing strategic developments.

Silence Therapeutics plc announced its acquisition of exclusive worldwide rights to two siRNA drug targets previously under collaboration with Mallinckrodt Pharmaceuticals. No upfront payment is required, but future success-based milestones and low royalties on net sales are expected. This strategic move aims to enhance Silence's portfolio in complement-mediated diseases, showcasing confidence in the mRNAi GOLD™ platform. The ongoing collaboration with Mallinckrodt since July 2019 will retain rights to the SLN501 program. Silence continues to focus on developing treatments for significant unmet medical needs in cardiovascular and hematological areas.

Silence Therapeutics plc (Nasdaq: SLN) reports its financial results for Q4 and full year 2022, highlighting a net loss of £40.5 million, up from £39.4 million in 2021. Revenue increased to £17.5 million from £12.4 million, attributed to advancing collaborations. R&D expenses rose to £35.6 million, reflecting enhanced clinical studies. Notably, the company is progressing with its clinical pipeline, including the SLN360 program for cardiovascular diseases and SLN124 for hematological conditions, with topline data expected in Q4 2023. As of December 31, 2022, liquidity stood at £71.1 million, sufficient to fund operations into Q1 2024.